Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - atovaquone ; proguanil hydrochloride - film coated tablet - 250/100 milligram - proguanil, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc.,usa - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt), proguanil hydrochloride (unii: r71y86m0wt) (proguanil - unii:s61k3p7b2v) - atovaquone 250 mg - atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. atovaquone and proguanil hydrochloride tablets are indicated for the treatment of acute, uncomplicated p. falciparum malaria. atovaquone and proguanil hydrochloride tablets have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance. risk summary available data from published literature and postmarketing experience with use of atovaquone and proguanil hydrochloride in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. the proguanil component of atovaquone and proguanil hydrochloride tablets acts to inhibit parasitic dihydrofolate reductase; however, pregnant women and females of reproductive potential should cont

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark arzneimittel gmbh - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - atovaquone; proguanil hydrochloride - film-coated tablet - 250/100 milligram(s) - biguanides; proguanil, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - proguanil hydrochloride; atovaquone - film-coated tablet - 250/100 milligram(s) - biguanides; proguanil, combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - atovaquone, quantity: 250 mg; proguanil hydrochloride, quantity: 100 mg - tablet - excipient ingredients: povidone; microcrystalline cellulose; poloxamer; sodium starch glycollate type a; hyprolose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 8000; iron oxide red; macrogol 400 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults.,? treatment of plasmodium falciparum malaria in adults.

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt), proguanil hydrochloride (unii: r71y86m0wt) (proguanil - unii:s61k3p7b2v) - atovaquone 250 mg - atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. atovaquone and proguanil hydrochloride tablets are indicated for the treatment of acute, uncomplicated p. falciparum malaria. atovaquone and proguanil hydrochloride tablets have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance. atovaquone and proguanil hydrochloride is contraindicated in individuals with known hypersensitivity reactions (e.g., anaphylaxis, erythema multiforme or stevens-johnson syndrome, angioedema, vasculitis) to atovaquone or proguanil hydrochloride or any component of the formulation. atovaquone and proguanil hydrochloride is contraindicated for prophylaxis of p. falciparum malaria in patients with sever

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; poloxamer; magnesium stearate; hyprolose; purified water; povidone; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: povidone; poloxamer; colloidal anhydrous silica; purified water; magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.